AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02468297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
Study NCT04291807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video education
Description: Procedure was presented to the cases via a video showing the steps in ERCP and questions had been answered by an experienced nurse
Study NCT00632086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA32540
Study NCT00632086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin component of PA32540
Description: The 325 mg aspirin component of PA32540
Study NCT00632086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ecotrin
Description: 325 mg Ecotrin
Study NCT00379990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW274150
Description: 60 mg /day
Study NCT00379990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 7.5 mg/day
Study NCT00379990 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03260075 — intervention group
Intervention type: OTHER
Intervention: cat
Description: Cat living at the ward
Study NCT02509494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit (Inf. U.).
Study NCT02509494 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
Study NCT02509494 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% saline for injection.
Study NCT00423085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Description: Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm\^2 (4.5 mg), 5 cm\^2 (9 mg), 7.5 cm\^2 (13.5 mg), and 10 cm\^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
Study NCT00423085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo transdermal patch was provided in the following sizes: 2.5 cm\^2, 5 cm\^2, 7.5 cm\^2 and 10 cm\^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
Study NCT02614313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open breath test with fructose
Description: Open randomised fructose 35g during breath test
Study NCT02614313 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Breath test with sweet placebo (Assugrin)
Description: Double-blind randomised breath-testing with sweet placebo (Assugrin)
Study NCT02614313 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Breath test with neutral placebo (still water)
Description: Double-blind randomised breath-testing with neutral placebo
Study NCT02614313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blinded breath test with fructose
Description: Double-blind randomised fructose 35g during breath test
Study NCT00734734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza Vaccine
Description: 1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
Study NCT01218789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg tasimelteon capsules, PO daily for 1 year
Study NCT02344407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSVG-ZEBOV
Description: The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)
Study NCT02344407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd3-EBO Z
Description: The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.
Study NCT02344407 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01070602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior (more central) corneal paracentesis incision
Description: 3 corneal paracentesis incisions will be located 1 mm anterior to the limbus.
Study NCT00213252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast plus prednisolone
Description: Single dose of oral prednisolone with a subsequent daily five-day course of oral Montelukast
Study NCT00213252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Six daily doses of oral prednisolone
Study NCT00407914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquamid
Description: Subcutaneous injection
Study NCT00407914 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Injection in dermis
Study NCT01238315 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HuCNS-SC
Description: Surgery to implant human CNS stem cells
Study NCT02507193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction internal fixation
Description: An incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
Study NCT02507193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermedullary Nail
Description: An incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
Study NCT04032171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants received evobrutinib twice daily (BID).
Study NCT04032171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex®
Description: Participants received avonex® IM injection once a week.
Study NCT04032171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex® matched Placebo
Description: Participants received IM injection of placebo matched to avonex® once a week.
Study NCT04032171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evobrutinib matched Placebo
Description: Participants received placebo matched to evobrutinib twice a day.
Study NCT02295735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex® Border Sacrum and Mepilex® Border Heel
Study NCT03007017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deceased donor nephrectomy, prior to cross clamp of donor aorta
Description: The investigators will perform a prospective investigation of organ recoveries during which the left kidney will be removed prior to cessation of cardiac activity. The second kidney will be removed in the standard fashion. To do this, investigators will adopt techniques used in living donor kidney transplantation. Specifically, a specialized vascular stapler will be used to divide the renal artery at the level of aorta, followed by the vein, at the level of the vena cava. As such, no cuff of abdominal aorta or vena cava will be present on the target kidneys. Once removed from the body, just as is done for living donor kidney transplantation, the kidneys will be immediately flushed. As this ex-vivo flush is already performed for cadaveric kidney transplantation, there should be no additional cost for performing this portion of the procedure. Approximately 15 minutes of additional surgical dissection (prior to stopping the heart) will be required under the proposed study.
Study NCT03007017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deceased donor nephrectomy, standard of care
Description: The investigators will remove the right kidney in the stand of care procedures for cadaveric kidney transplantation
Study NCT03147339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGEs restricted diet
Description: Diet modification to reduce advanced glycation end products in diet. for example to change ways of cooking, time of cooking and also omit some foods.
Study NCT02565771 — intervention group
Intervention type: OTHER
Intervention: Adapted physical activity
Description: The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
Study NCT02913222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Comparison of two rehabilitation approaches
Study NCT02913222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Comparison of two rehabilitation approaches
Study NCT02776410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consumer reactions to tailored messages sent via app
Description: The intervention will take 1 month. Participants from the Intervention group will receive tailored messages every 2-3 days with a push notification. Additionally, interaction with the participants via the use of app is foreseen.
Study NCT03873402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03873402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT03873402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ipilimumab placebo
Description: Specified dose on specified days
Study NCT02498756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells
Description: CIK cells are transferred every 3 months for 1 year.
Study NCT01162876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxaglipitin
Description: oral administration of 5 mg tablet before breakfast for 14 consecutive days
Study NCT02498756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab are delivered every 3 weeks for one year
Study NCT02498756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab are delivered every 3 weeks for one year
Study NCT03357146 — intervention group
Intervention type: DEVICE
Intervention: Optical coherence tomography angiography
Description: OCTA scans per built-in device protocol
Study NCT00037635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 073
Description: 30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
Study NCT00037635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
Study NCT00209521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fospropofol
Description: Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from AQUAVAN were 0.7 μg/mL (sedation) and 2.5 μg/mL (maintain anesthesia).
Study NCT00209521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from Disoprivan were 1.0 μg/mL (sedation) and 3.0 μg/mL (maintain anesthesia).
Study NCT03653403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-126 Gel
Description: Component A
Study NCT03653403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Gel
Description: gel
Study NCT02626845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.
Study NCT02626845 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.
Study NCT01202721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Atenolol or matching placebo 25 mg up-titrated to 100 mg
Study NCT01202721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan or matching placebo 40 mg up-titrated to 80mg.
Study NCT00247182 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Step 1: Minimal Intervention
Description: All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments
Study NCT00247182 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Step 2: Brief Motivational Intervention
Description: Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
Study NCT00247182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step 2: Brief Motivational Intervention
Description: Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
Study NCT00247182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Assessment
Description: Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
Study NCT03265743 — intervention group
Intervention type: OTHER
Intervention: Self-report Written Questionnaire
Description: Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.
Study NCT03798249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Description: Tereos
Study NCT03798249 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nestlé Health Science
Study NCT01547910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish oil given in supplementary dose
Study NCT01547910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish Oil
Description: Fish oil given in supplementary dose
Study NCT02725827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EmbryoGlue (Vitrolife)
Description: A hyaluronan-enriched embryo transfer medium
Study NCT02725827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control medium
Description: The usual embryo transfer medium used in the study centres.
Study NCT02474524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health intervention
Description: Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker, in addition to their routine care. Sessions will be structured by the worker and participant using a tablet computer to view materials on mental health self-management and personal recovery on a dedicated website for the trial. These will include information, videos, audio and exercises. Online materials make particular use of videos featuring people with lived experience of psychosis discussing how they have dealt with issues in their recovery, and will allow users to post comments on videos and in a forum. Participants may access online materials both during intervention sessions and outside sessions using any Internet-enabled device.
Study NCT02474524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social intervention
Description: Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker in addition to routine care (treatment as usual). The social intervention will utilise a computer tablet (i.e., iPad) servicing online resources to extend a manualised befriending intervention, based upon social interaction, designed to control for therapist contact and computer use. Each session will involve interaction about non-health related topics of interest to the participants, which will be facilitated by use of viewing online material related to these interests on a tablet computer as a prompt to conversation.
Study NCT03802708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Metabolomic analysis urine sample
Description: a urine sample will be anlayzed for metabolic pathways involving Nitric Oxide Nitric Oxide level will be measured at the exhaled air sample
Study NCT04178239 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI, questionnaires, pneumologic diagnostics
Description: fMRI neuropsychological questionnaires pneumologic diagnostics: blood samples, whole body plethysmography, walking test
Study NCT02178111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Never perform episiotomy
Description: In this group birth attendants will be sought to avoid at all cost episiotomy. The intention is to never perform episiotomy in this group.
Study NCT03923699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anesthesia Control Tower monitoring
Description: Real time data will be monitored through the AlertWatch® system as well as the patient's EHR.
Study NCT02178111 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: episiotomy
Study NCT03045354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mashed potatoes
Description: Isocaloric (450 kcal) breakfast treatments of eggs with a side of mashed potatoes
Study NCT03045354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional breakfast
Description: Isocaloric (450 kcal) control breakfast treatments of cereal, milk, toast and jam
Study NCT03045354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast skipping
Description: No breakfast
Study NCT03045354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: French fries
Description: Isocaloric (450 kcal) breakfast treatments of eggs with a side of French fries
Study NCT03045354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beans
Description: Isocaloric (450 kcal) breakfast treatments of eggs with a side of beans
Study NCT00629941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaSite®
Description: Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Study NCT04004468 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Standard barbell resistance training programs
Study NCT01135511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 Eye drops
Description: Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
Study NCT01135511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 Eye drops
Description: Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
Study NCT01135511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 Eye drops
Description: Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
Study NCT01135511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-690,550 Eye drops-vehicle
Description: Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
Study NCT01135511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Ophthalmic topical solution, dosed 6 times/day, 8 weeks
Study NCT02748265 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled Epoprostenol and phenylephrine
Description: After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously
Study NCT02748265 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: Volatile maintenance anesthesia
Study NCT02748265 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Intravenous maintenance anesthesia
Study NCT04679571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Patients with serum albumin \<3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin >3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin >3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks.